Tuesday 1 April 2025 06:55 GMT

Matthew Perry's Final Days: Shocking Documentary Reveals 27 Ketamine Shots Before Death


(MENAFN- Live Mint) A new documentary, Matthew Perry: A Hollywood Tragedy, has revealed shocking details about the Friends star's final days. According to US Attorney Martin Estrada, Perry received a total of 27 ketamine shots in the three days leading up to his death at age 54 in October 2023.

Drug suppliers face scrutiny

Estrada, who oversaw the investigation into Matthew Perry's death , emphasised that those involved in supplying the drugs should be held accountable.“Dr. Plasencia was very clear in text messages... that he saw this as an opportunity to make a lot of money in a short amount of time , and he allegedly did just that,” Estrada stated in the documentary.

Blame on drug suppliers

Estrada also highlighted a shift in how authorities view drug-related deaths.“In the past, we used to call these things overdose deaths and do more blaming of the victim,” he said.“We don't do that anymore. We blame the drug dealers, the drug sellers, for taking advantage of those addiction issues to cause death or serious injury, and that's why we bring these cases.”

Autopsy report and cause of death

According to the autopsy report, Perry's cause of death was ruled as“acute effects of ketamine,” with the manner of death listed as accidental drowning.

Five arrests in connection with Perry's death

The documentary also sheds light on the five individuals arrested in connection with Perry's death . Among them are two doctors, his live-in personal assistant, and an alleged drug dealer known as the“Ketamine Queen.”

Upcoming trials and guilty pleas

Dr. Salvador Plasencia and Jasveen Sangha, dubbed the“Ketamine Queen,” have both pleaded not guilty and are set to stand trial on March 4, 2025. Meanwhile, Perry 's former live-in personal assistant, Kenneth Iwamasa, pleaded guilty on August 7, 2024, to one count of conspiracy to distribute ketamine causing death.

MENAFN26022025007365015876ID1109253944


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Search